Norman L. Wright
Norman L. Wright's purchase track record
Norman L. Wright has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/9/2025 | OPCH | $100K | +10.2% | +1.2% | +4.1% |
| 3/7/2023 | FSLR | $100K | -8.2% | -13.0% | +12.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.
Transaction History
| FSLR | ▲ Buy | Grant | 300 | $0 | 9/30/2026 | View on chart |
| FSLR | ▲ Buy | Grant | 223 | $0 | 6/30/2026 | View on chart |
| OPCH | ▲ Buy | Grant | 8,997 | $0 | 5/20/2026 | View on chart |
| FSLR | ▲ Buy | Grant | 267 | $0 | 3/31/2026 | View on chart |
| FSLR | ▲ Buy | Grant | 173 | $0 | 12/31/2025 | View on chart |
| FSLR | ▲ Buy | Grant | 205 | $0 | 9/30/2025 | View on chart |
| OPCH | ▲ Buy | Open Market | 3,411 | $100K | 9/9/2025 | View on chart |
| FSLR | ▲ Buy | Grant | 272 | $0 | 6/30/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 5,034 | $0 | 5/14/2025 | View on chart |
| FSLR | ▲ Buy | Grant | 356 | $0 | 3/31/2025 | View on chart |
| FSLR | ▲ Buy | Grant | 256 | $0 | 12/31/2024 | View on chart |
| FSLR | ▲ Buy | Grant | 181 | $0 | 9/30/2024 | View on chart |
| FSLR | ▲ Buy | Grant | 200 | $0 | 6/28/2024 | View on chart |
| OPCH | ▲ Buy | Grant | 5,325 | $0 | 5/15/2024 | View on chart |
| OPCH | ▲ Buy | Grant | 1,731 | $0 | 4/1/2024 | View on chart |
| FSLR | ▲ Buy | Grant | 267 | $0 | 3/29/2024 | View on chart |
| FSLR | ▲ Buy | Grant | 262 | $0 | 12/29/2023 | View on chart |
| FSLR | ▲ Buy | Grant | 279 | $0 | 9/30/2023 | View on chart |
| FSLR | ▲ Buy | Grant | 237 | $0 | 6/30/2023 | View on chart |
| FSLR | ▲ Buy | Grant | 207 | $0 | 3/31/2023 | View on chart |
| FSLR | ▲ Buy | Open Market | 465 | $100K | 3/7/2023 | View on chart |
| FSLR | ▲ Buy | Grant | 268 | $0 | 12/30/2022 | View on chart |
| FSLR | ▲ Buy | Grant | 303 | $0 | 9/30/2022 | View on chart |
| FSLR | ▲ Buy | Grant | 588 | $0 | 6/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
First Solar Faces Solar Sector Headwinds and Rate Concerns
First Solar is navigating a challenging environment marked by broader solar industry weakness and concerns about higher interest rates impacting clean tech valuations. While Barclays maintains an Overweight rating, it recently lowered its price target to $259. The company is scheduled to report its third-quarter financial results on October 29, 2026, which will be a key moment for assessing its performance against these macroeconomic headwinds.
First Solar Faces Solar Sector Headwinds and Rate Concerns. First Solar is navigating a challenging environment marked by broader solar industry weakness and concerns about higher interest rates impacting clean tech valuations. While Barclays maintains an Overweight rating, it recently lowered its price target to $259. The company is scheduled to report its third-quarter financial results on October 29, 2026, which will be a key moment for assessing its performance against these macroeconomic headwinds.